comprehensive -WSS

comprehensive

author：comprehensive 2025-09-03 03:32:47 - browse：746

Adobe

The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： The Readout: Lenmeldy, GLP

hotspot

explore

WSS

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Orchard's therapy for neuron disease in children wins FDA approval

Intermittent fasting comes with a heart risk? Not so fast

Intermittent fasting comes with a heart risk? Not so fast

Supreme Court mifepristone arguments center on docs' right to sue

Merck drug for rare lung condition set for approval in U.S.

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

entertainment

New air purifier tech could be key to improving indoor air quality

Patient advocates debate FDA's accelerated approval process

How one medical school became remarkably diverse

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Medicare details structure of new drug price negotiation program

Vertex Pharmaceuticals may move headquarters in Boston

Psychedelics group wrestles with new pharma identity

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Jerome Adams on the need for new antivirals for Covid

Primary care physicians play key roles in Alzheimer's management

hotspot

Food as medicine: Medically tailored meals may get standardized

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Asbestos, a deadly carcinogen, banned by EPA

App could help diagnose ear infections more accurately — and at home

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Scientists boost immune system in aging mice by making it youthful

leisure time

hotspot

explore

explore